|
1
|
Rahman L, Voeller D, Rahman M, et al:
Thymidylate synthase as an oncogene: a novel role for an essential
DNA synthesis enzyme. Cancer Cell. 5:341–351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ciuleanu T, Brodowicz T, Zielinski C, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: a
randomised, double-blind, phase III study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scagliotti G, Brodowicz T, Shepherd FA, et
al: Treatment-byhistology interaction analyses in three phase III
trials show superiority of pemetrexed in nonsquamous non-small cell
lung cancer. J Thorac Oncol. 6:64–70. 2011.PubMed/NCBI
|
|
6
|
Tanaka F, Wada H, Fukui Y and Fukushima M:
Thymidylate synthase gene expression in primary lung cancer
patients: a large-scale study in Japanese population. Ann Oncol.
22:1791–1797. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaira K, Ohde Y, Nakagawa K, Okumura T, et
al: Thymidylate synthase expression is closely associated with
outcomes in patients with pulmonary adenocarcinoma. Med Oncol.
29:1663–1672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun JM, Han J, Ahn JS, Park K and Ahn MJ:
Significance of thymidylate synthase and thyroid transcription
factor 1 expression in patients with nonsquamous non-small cell
lung cancer treated with pemetrexed-based treatment. J Thorac
Oncol. 6:1392–1399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Bock CE, Garg MB, Scott N, Sakoff JA,
Scorgie FE, Ackland SP and Lincz LF: Association of thymidylate
synthase enhancer region polymorphisms with thymidylate synthase
activity in vivo. Pharmacogenomics J. 11:307–314. 2011.PubMed/NCBI
|
|
10
|
Mandola MV, Stoehlmacher J, Zhang W, et
al: A 6 bp polymorphism in the thymidylate synthase gene causes
message instability and is associated with decreased intratumoral
TS mRNA levels. Pharmacogenetics. 14:319–327. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mandola MV, Stoehlmacher J, Muller-Weeks
S, Cesarone G, Yu MC, Lenz HJ and Ladner RD: Ladner, a novel single
nucleotide polymorphism within the 5′ tandem repeat polymorphism of
the thymidylate synthase gene abolishes USF-1 binding and alters
transcriptional activity. Cancer Res. 63:2898–2904. 2003.
|
|
12
|
Lurje G, Manegold PC, Ning Y, Pohl A,
Zhang W and Lenz HJ: Thymidylate synthase gene variations:
predictive and prognostic markers. Mol Cancer Ther. 8:1000–1007.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shitara K, Muro K, Ito S, et al: Folate
intake along with genetic polymorphisms in
methylenetetrahydrofolate reductase and thymidylate synthase in
patients with advanced gastric cancer. Cancer Epidemiol Biomarkers
Prev. 19:1311–1319. 2010. View Article : Google Scholar
|
|
14
|
Kumar K, Vamsy M and Jamil K: Thymidylate
synthase gene polymorphisms effecting 5-FU response in breast
cancer patients. Cancer Biomark. 6:83–93. 2010.PubMed/NCBI
|
|
15
|
Takehara A, Kawakami K, Ohta N, Oyama K,
Ota Y, Oda M and Watanabe G: Prognostic significance of the
polymorphisms in thymidylate synthase and methylenetetrahydrofolate
reductase gene in lung cancer. Anticancer Res. 25:4455–4461.
2005.
|
|
16
|
Sobin LH, Gospodarowicz MK and Wittekind
CH: International Union Against Cancer (UICC) TNM Classification of
Malignant Tumours. 7th edition. Wiley-Blackwell; Oxford: pp. 1–256.
2009
|
|
17
|
Edge SB, Byrd DR, Carducci MA, et al:
American Joint Committee on Cancer (AJCC) Cancer Staging Handbook.
7th edition. Springer-Verlag; New York: pp. 1–195. 2009
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
19
|
Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K and
Feng JF: Polymorphism in the 3′-untranslated region of the
thymidylate synthase gene and sensitivity of stomach cancer to
fluoropyrimidine-based chemotherapy. J Hum Genet. 51:155–160.
2006.
|
|
20
|
Ettinger DS, Akerley W, Borghaei H, et al:
NCCN Clinical Practice Guidelines in Oncology. version 2.2012.
National Comprehensive Cancer Network; Fort Washington, PA: pp.
1–112. 2011, Available at https://www.nccn.com.
|
|
21
|
Huang ZH, Hua D and Li LH: The
polymorphisms of TS and MTHFR predict survival of gastric cancer
patients treated with fluorouracil-based adjuvant chemotherapy in
Chinese population. Cancer Chemother Pharmacol. 63:911–918. 2009.
View Article : Google Scholar
|
|
22
|
Giovannetti E, Backus HH, Wouters D, et
al: Changes in the status of p53 affect drug sensitivity to
thymidylate synthase (TS) inhibitors by altering TS levels. Br J
Cancer. 96:769–775. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gorlick R, Metzger R, Danenberg KD, et al:
Higher levels of thymidylate synthase gene expression are in
pulmonary as compared with hepatic metastases of colorectal
adenocarcinoma. J Clin Oncol. 16:1465–1469. 1998.PubMed/NCBI
|
